Toxicological Evaluation of Intravenous Formulation of Rifapentine

Rifapentine belongs to the most potent antituberculosis drugs. Nevertheless, there are some limitations for its clinical use because of the low aqueous solubility and side effects. A technological approach to development of rifapentine intravenous formulation based on human serum albumin was describ...

Full description

Saved in:
Bibliographic Details
Main Authors: K. P. Ostrovskiy, E. R. Pereverzeva, I. D. Treshchalin, N. S. Osipova, M. I. Treshchalin, E. V. Voznyakovskaya, V. Yu. Balabanyan, O. O. Maksimenko, S. E. Gelperina
Format: Article
Language:Russian
Published: LLC "Publishing House OKI" 2020-05-01
Series:Антибиотики и Химиотерапия
Subjects:
Online Access:https://www.antibiotics-chemotherapy.ru/jour/article/view/674
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849389337063456768
author K. P. Ostrovskiy
E. R. Pereverzeva
I. D. Treshchalin
N. S. Osipova
M. I. Treshchalin
E. V. Voznyakovskaya
V. Yu. Balabanyan
O. O. Maksimenko
S. E. Gelperina
author_facet K. P. Ostrovskiy
E. R. Pereverzeva
I. D. Treshchalin
N. S. Osipova
M. I. Treshchalin
E. V. Voznyakovskaya
V. Yu. Balabanyan
O. O. Maksimenko
S. E. Gelperina
author_sort K. P. Ostrovskiy
collection DOAJ
description Rifapentine belongs to the most potent antituberculosis drugs. Nevertheless, there are some limitations for its clinical use because of the low aqueous solubility and side effects. A technological approach to development of rifapentine intravenous formulation based on human serum albumin was described earlier and its efficacy against experimental tuberculosis was estimated. Toxicological evaluation of that water-compatible form of rifapentine revealed its low acute toxicity (LD50 340 mg/kg). Chronic toxicity tests of both the oral substance and the injectable formulation of rifapentine demonstrated similar adverse effects. However, in contrast to the conventional oral formulations, the intravenous formulation of rifapentine had no gastrointestinal toxic effects or cardiotoxicity, thus suggesting its usefulness for clinical application.
format Article
id doaj-art-8653fe55e53f4f5db7c05759bdb38e7c
institution Kabale University
issn 0235-2990
language Russian
publishDate 2020-05-01
publisher LLC "Publishing House OKI"
record_format Article
series Антибиотики и Химиотерапия
spelling doaj-art-8653fe55e53f4f5db7c05759bdb38e7c2025-08-20T03:42:00ZrusLLC "Publishing House OKI"Антибиотики и Химиотерапия0235-29902020-05-01617-81521673Toxicological Evaluation of Intravenous Formulation of RifapentineK. P. Ostrovskiy0E. R. Pereverzeva1I. D. Treshchalin2N. S. Osipova3M. I. Treshchalin4E. V. Voznyakovskaya5V. Yu. Balabanyan6O. O. Maksimenko7S. E. Gelperina8Drugs Technology LLCG.F.Gause Research Institute of New AntibioticsG.F.Gause Research Institute of New AntibioticsDrugs Technology LLCG.F.Gause Research Institute of New AntibioticsG.F.Gause Research Institute of New AntibioticsDrugs Technology LLCDrugs Technology LLCDrugs Technology LLCRifapentine belongs to the most potent antituberculosis drugs. Nevertheless, there are some limitations for its clinical use because of the low aqueous solubility and side effects. A technological approach to development of rifapentine intravenous formulation based on human serum albumin was described earlier and its efficacy against experimental tuberculosis was estimated. Toxicological evaluation of that water-compatible form of rifapentine revealed its low acute toxicity (LD50 340 mg/kg). Chronic toxicity tests of both the oral substance and the injectable formulation of rifapentine demonstrated similar adverse effects. However, in contrast to the conventional oral formulations, the intravenous formulation of rifapentine had no gastrointestinal toxic effects or cardiotoxicity, thus suggesting its usefulness for clinical application.https://www.antibiotics-chemotherapy.ru/jour/article/view/674poor soluble antibioticstuberculosisrifapentineacute toxicitychronic toxicity
spellingShingle K. P. Ostrovskiy
E. R. Pereverzeva
I. D. Treshchalin
N. S. Osipova
M. I. Treshchalin
E. V. Voznyakovskaya
V. Yu. Balabanyan
O. O. Maksimenko
S. E. Gelperina
Toxicological Evaluation of Intravenous Formulation of Rifapentine
Антибиотики и Химиотерапия
poor soluble antibiotics
tuberculosis
rifapentine
acute toxicity
chronic toxicity
title Toxicological Evaluation of Intravenous Formulation of Rifapentine
title_full Toxicological Evaluation of Intravenous Formulation of Rifapentine
title_fullStr Toxicological Evaluation of Intravenous Formulation of Rifapentine
title_full_unstemmed Toxicological Evaluation of Intravenous Formulation of Rifapentine
title_short Toxicological Evaluation of Intravenous Formulation of Rifapentine
title_sort toxicological evaluation of intravenous formulation of rifapentine
topic poor soluble antibiotics
tuberculosis
rifapentine
acute toxicity
chronic toxicity
url https://www.antibiotics-chemotherapy.ru/jour/article/view/674
work_keys_str_mv AT kpostrovskiy toxicologicalevaluationofintravenousformulationofrifapentine
AT erpereverzeva toxicologicalevaluationofintravenousformulationofrifapentine
AT idtreshchalin toxicologicalevaluationofintravenousformulationofrifapentine
AT nsosipova toxicologicalevaluationofintravenousformulationofrifapentine
AT mitreshchalin toxicologicalevaluationofintravenousformulationofrifapentine
AT evvoznyakovskaya toxicologicalevaluationofintravenousformulationofrifapentine
AT vyubalabanyan toxicologicalevaluationofintravenousformulationofrifapentine
AT oomaksimenko toxicologicalevaluationofintravenousformulationofrifapentine
AT segelperina toxicologicalevaluationofintravenousformulationofrifapentine